These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 12584036)
21. Effects of intravenous pamidronate therapy on Paget's disease of bone. Bombassei GJ; Yocono M; Raisz LG Am J Med Sci; 1994 Oct; 308(4):226-33. PubMed ID: 7942981 [TBL] [Abstract][Full Text] [Related]
22. Paget's disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate. Filipponi P; Cristallini S; Policani G; Casciari C; Gregorio F Bone; 1998 Dec; 23(6):543-8. PubMed ID: 9855463 [TBL] [Abstract][Full Text] [Related]
23. [Bisphosphonate therapy of Paget's disease of bone with pamidronate]. Grauer A; Klar B; Knaus J; Scharla SH; Ziegler R Med Klin (Munich); 1996 Jan; 91(1):14-9. PubMed ID: 8839196 [TBL] [Abstract][Full Text] [Related]
24. Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another. Gutteridge DH; Ward LC; Stewart GO; Retallack RW; Will RK; Prince RL; Criddle A; Bhagat CI; Stuckey BG; Price RI; Kent GN; Faulkner DL; Geelhoed E; Gan SK; Vasikaran S J Bone Miner Res; 1999 Oct; 14 Suppl 2():79-84. PubMed ID: 10510219 [TBL] [Abstract][Full Text] [Related]
25. Clinical experience with pamidronate in the treatment of Paget's disease of bone. Gallacher SJ; Boyce BF; Patel U; Jenkins A; Ralston SH; Boyle IT Ann Rheum Dis; 1991 Dec; 50(12):930-3. PubMed ID: 1768163 [TBL] [Abstract][Full Text] [Related]
26. High-dose pamidronate in the management of resistant Paget's disease. Cundy T; Wattie D; King AR Calcif Tissue Int; 1996 Jan; 58(1):6-8. PubMed ID: 8825232 [TBL] [Abstract][Full Text] [Related]
27. Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo controlled trial. Erdtsieck RJ; Pols HA; Valk NK; van Ouwerkerk BM; Lamberts SW; Mulder P; Birkenhäger JC Clin Endocrinol (Oxf); 1995 Nov; 43(5):557-65. PubMed ID: 8548940 [TBL] [Abstract][Full Text] [Related]
28. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. Monegal A; Guañabens N; Suárez MJ; Suárez F; Clemente G; García-González M; De la Mata M; Serrano T; Casafont F; Tome S; Barrios C; Navasa M Transpl Int; 2009 Feb; 22(2):198-206. PubMed ID: 18796000 [TBL] [Abstract][Full Text] [Related]
29. [Therapy of Paget's disease with bisphosphonate pamidronate (AHPrBP, formerly APD)]. Scharla SH; Grauer A; Ziegler R Klin Wochenschr; 1991 Jan; 69(1):25-30. PubMed ID: 2016845 [TBL] [Abstract][Full Text] [Related]
30. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis. Vis M; Bultink IE; Dijkmans BA; Lems WF Osteoporos Int; 2005 Nov; 16(11):1432-5. PubMed ID: 15883662 [TBL] [Abstract][Full Text] [Related]
31. Long-term change in the bone mineral density of adults with adult onset growth hormone (GH) deficiency in response to short or long-term GH replacement therapy. Rahim A; Holmes SJ; Adams JE; Shalet SM Clin Endocrinol (Oxf); 1998 Apr; 48(4):463-9. PubMed ID: 9640413 [TBL] [Abstract][Full Text] [Related]
32. [A single infusion of Pamidronate (APD) in Paget's disease of bone]. Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P Schweiz Med Wochenschr; 1989 Jan; 119(3):71-4. PubMed ID: 2711157 [TBL] [Abstract][Full Text] [Related]
33. Intravenously administered pamidronate in the treatment of Paget's disease of bone. Tucci JR; Bontha S Endocr Pract; 2001; 7(6):423-9. PubMed ID: 11747277 [TBL] [Abstract][Full Text] [Related]
34. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone. Thiébaud D; Jaeger P; Gobelet C; Jacquet AF; Burckhardt P Am J Med; 1988 Aug; 85(2):207-12. PubMed ID: 3261129 [TBL] [Abstract][Full Text] [Related]
35. Further increase in forearm cortical bone mineral content after discontinuation of growth hormone replacement. Holmes SJ; Whitehouse RW; Economou G; O'Halloran DJ; Adams JE; Shalet SM Clin Endocrinol (Oxf); 1995 Jan; 42(1):3-7. PubMed ID: 7889628 [TBL] [Abstract][Full Text] [Related]
36. Bone histomorphometry in Paget's disease. Quantitative and dynamic analysis of pagetic and nonpagetic bone tissue. Meunier PJ; Coindre JM; Edouard CM; Arlot ME Arthritis Rheum; 1980 Oct; 23(10):1095-103. PubMed ID: 7426075 [TBL] [Abstract][Full Text] [Related]
37. Tubular excretion of phosphate in Paget's disease of bone. Effect of pamidronate. Constantin A; Laroche M; Moulinier L; Bon E; Ramonjisoa M; Cantagrel A; Mazieres B Rev Rhum Engl Ed; 1995; 62(7-8):493-500. PubMed ID: 8574612 [TBL] [Abstract][Full Text] [Related]
38. Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD). Stone MD; Hawthorne AB; Kerr D; Webster G; Hosking DJ J Bone Miner Res; 1990 Dec; 5(12):1231-5. PubMed ID: 2075835 [TBL] [Abstract][Full Text] [Related]
39. Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety. Ryan PJ; Blake GM; Davie M; Haddaway M; Gibson T; Fogelman I Osteoporos Int; 2000; 11(2):171-6. PubMed ID: 10793877 [TBL] [Abstract][Full Text] [Related]
40. Dual-energy X-ray absorptiometry and quantitative ultrasound in patients with Paget's disease of bone before and after treatment with zoledronic acid: association with serum bone markers and Dickkopf-1. Polyzos SA; Anastasilakis AD; Litsas I; Sapranidis M; Efstathiadou Z; Kita M; Arsos G; Moralidis E; Zafeiriadou E; Papatheodorou A; Terpos E J Clin Densitom; 2010; 13(2):190-6. PubMed ID: 20347367 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]